{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:26:39Z","timestamp":1747171599265,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.therap.2017.08.001","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T14:20:24Z","timestamp":1507818024000},"page":"283-285","source":"Crossref","is-referenced-by-count":1,"title":["Hypercalc\u00e9mie sous \u00e9tanercept\u00a0: \u00e0 quoi faut-il penser\u00a0?"],"prefix":"10.1016","volume":"73","author":[{"given":"Cl\u00e9mentine","family":"Gondolf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Baudart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Fedrizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7905-0956","authenticated-orcid":false,"given":"St\u00e9phane","family":"Allouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.therap.2017.08.001_bib0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/10408449991349258","article-title":"Tumor necrosis factor alpha and toxicology","volume":"29","author":"Luster","year":"1999","journal-title":"Crit Rev Toxicol"},{"issue":"7","key":"10.1016\/j.therap.2017.08.001_bib0010","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.therap.2017.08.001_bib0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.therap.2017.08.001_bib0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.therap.2017.08.001_bib0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Wegener's","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.therap.2017.08.001_bib0030","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.revmed.2010.02.007","article-title":"TNF\u03b1 blocking agents and sarcoidosis: an update","volume":"31","author":"Toussirot","year":"2010","journal-title":"Rev Med Interne"},{"issue":"3","key":"10.1016\/j.therap.2017.08.001_bib0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.rmr.2013.04.029","article-title":"Severe hypercalcemia revealing sarcoidosis precipitated by etanercept","volume":"31","author":"Watrin","year":"2014","journal-title":"Rev Mal Respir"},{"issue":"6","key":"10.1016\/j.therap.2017.08.001_bib0040","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5603\/PiAP.2015.0076","article-title":"Selected molecular events in the pathogenesis of sarcoidosis \u2013\u00a0recent advances","volume":"83","author":"Kisza\u0142kiewicz","year":"2015","journal-title":"Pneumonol Alergol Pol"},{"key":"10.1016\/j.therap.2017.08.001_bib0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"Broos","year":"2013","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.therap.2017.08.001_bib0050","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.rmr.2010.08.018","article-title":"Pulmonary sarcoidosis developing during treatment with etanercept","volume":"28","author":"Kerjouan","year":"2011","journal-title":"Rev Mal Respir"},{"issue":"34","key":"10.1016\/j.therap.2017.08.001_bib0055","doi-asserted-by":"crossref","first-page":"A57","DOI":"10.1016\/j.revmed.2013.03.272","article-title":"Pseudosarco\u00efdose induite par les anti-TNF\u00a0: \u00e0 propos de quatre cas et revue de la litt\u00e9rature (46\u00a0cas)","volume":"34","author":"Guery","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2017.08.001_bib0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"issue":"1","key":"10.1016\/j.therap.2017.08.001_bib0065","first-page":"133","article-title":"Etiology of sarcoidosis: does infection play a role?","volume":"85","author":"Shiv Saidha","year":"2012","journal-title":"Yale J Biol Med"},{"issue":"11","key":"10.1016\/j.therap.2017.08.001_bib0070","doi-asserted-by":"crossref","first-page":"21463","DOI":"10.3390\/ijms141121463","article-title":"Imbalance between Th17\u00a0and regulatory T-cells in sarcoidosis","volume":"14","author":"Huang","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.therap.2017.08.001_bib0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s13075-016-1197-5","article-title":"Increase in circulating Th17\u00a0cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis","volume":"18","author":"Hull","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.therap.2017.08.001_bib0080","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrrheum.2016.145","article-title":"Therapy: paradoxical effects of targeting TNF signalling in the treatment of autoimmunity","volume":"12","author":"Chen","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.therap.2017.08.001_bib0085","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","article-title":"Paradoxical inflammation induced by anti-TNF agents in patients with IBD","volume":"9","author":"Cleynen","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.therap.2017.08.001_bib0090","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.rmr.2010.06.011","article-title":"Infliximab treatment for chronic sarcoidosis \u2013\u00a0a case series","volume":"27","author":"Jounieaux","year":"2010","journal-title":"Rev Mal Respir"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717301531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717301531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T08:17:50Z","timestamp":1554279470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595717301531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0040595717301531"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2017.08.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}